logo
TakedaPresentsNewDataShowingMezagitamab(TAK-079)SustainedEffectonKidneyFunction18MonthsAfterTreatmentinPrimaryIgANephropathy
===2025/11/10 15:13:58===
ess release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking stateme
=*=*=*=*=*=
当前为第11/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页